Scaling and Automating CGT with Digital Innovation

The following is a summary from an episode of the 'Ori Spotlight' podcast featuring Anshul Mangal, President | Project Farma

Anshul Mangal, President at Project Farma was invited to join Ori Biotech CEO Jason C. Foster on the Ori Spotlight Podcast for an in-depth conversation about the challenges and opportunities in cell and gene therapy (CGT). In this engaging episode, Anshul shares his wealth of knowledge on the hurdles to scalable CGT development, stressing the critical importance of early strategic planning to set the stage for long-term success.

Together, they cover how digitalization is transforming CGT by improving manufacturing efficiency and reducing costs — a crucial factor for the future of advanced therapies — the evolving landscape of regulatory standards, and the exciting potential of distributed manufacturing to reshape the industry.

Interested in the full discussion? Tune in to the 'Ori Spotlight' podcast to hear the complete conversation and to learn more insights for advancing CGT to the next level. Click here to listen now!

About Project Farma

Project Farma, a Precision for Medicine company, specializes in providing comprehensive biomanufacturing strategies and execution services. We have successfully industrialized over 10 commercial cell, gene, and novel therapies, executed 60+ facility builds and capital expansions, and managed $6B+ in technical operations capital investments.

With expertise spanning startups, leading life science corporations, advanced therapy organizations, universities, hospitals, government agencies, and more, our team delivers proven technical operations and manufacturing solutions that shorten time-to-market, helping patients in need.

Visit our website to learn more about Project Farma and how Precision for Medicine’s integrated capabilities—across labs, clinical trials, manufacturing, and data intelligence—can help your organization bring therapies to life.